

Cladribine for treating relapsing–remitting multiple sclerosis

Information for the public

Published: 19 December 2019

Last updated: 21 May 2024

www.nice.org.uk

Cladribine (Mavenclad) is available on the NHS as a possible treatment for highly active multiple sclerosis in adults who have:

- rapidly evolving severe relapsing–remitting multiple sclerosis, that is with:
 - 2 or more relapses in the previous year and
 - baseline MRI evidence of disease activity, or
- relapsing–remitting multiple sclerosis that has not responded well enough to disease-modifying therapy (that is, 1 relapse in the previous year and MRI evidence of disease activity).

If you are not eligible for cladribine but are already taking it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Multiple Sclerosis Society](#), 0808 800 8000
- [Multiple Sclerosis Trust](#), 0800 032 3839

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-6148-1